NPC1L1 and hyperlipidemia: Masuda, D. et al. studied the effect of ezetimibe, which inhibits the Niemann–Pick C1-Like 1 (NPC1L1) protein, an intestinal cholesterol transporter, on postprandial hyperlipidemia in patients with type IIb hyperlipidemia, by performing an OFLT [14].